Skip to content

Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy

Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05486897
Acronym
PVWMH
Enrollment
315
Registered
2022-08-04
Start date
2022-09-05
Completion date
2023-12-15
Last updated
2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Amyloid Angiopathy, Hypertensive Arteriopathy

Brief summary

White matter hyperintensities (WMH) are one of the small vessel disease-related MRI characteristics of both cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HA). WMH tend to show a peri-basal ganglia pattern in HA, whereas a multiple subcortical spots pattern can be observed in CAA. Periventricular WMH (PVWMH) have been reported to be posterior predominant using a semiautomated segmentation method and logarithmic transformation, not used in daily clinical practice. In these studies including CAA patients, patients initially presented with haemorrhage-related symptoms. In another study analysing PVWMH and cerebral amyloid evidence in patients with mild cognitive impairment, frontal PVWMH burden was associated with high uptake on florbetapir-PET whereas parietal and occipital PVWMH burden was associated with low CSF-amyloid-beta. The aim of this study is the descriptive comparative analysis of the distribution of PVWMH between CAA and HA patients with radiological tools available in daily practice.

Interventions

None, pure observational study

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

CAA and HA patients, managed at Nîmes University Hospital between January 2015 and March 2022.

Exclusion criteria

CAA and HA patients, treated at the CHU of Nîmes between January 2015 and March 2022, not objecting to the use of their health data

Design outcomes

Primary

MeasureTime frameDescription
Distribution of PVWMHBase line, Day 0Maximal distance between the outer PVWMH border and the border of the lateral ventricle (on the axis oriented at 90° to the border of the ventricle)
Distribution of PVWMH - total PVWMH extent.Base line, Day 0The sum of the PVWMH measurements around the four ventricles horns (i.e. bilateral anterior and posteriors horns) resulted in total PVWMH extent.
Corpus callosum (CC) WMHBase line, Day 0Distance between the border of the third ventricle and the outer border of the WMH on the rostro-caudal axis, resulting in anterior and posterior CC-PVWMH extent measurements.
Corpus callosum (CC) WMH - total CC-PVWMH extent.Base line, Day 0The sum of the anterior and posterior CC-PVWMH measurements resulted in the total CC-PVWMH extent.
Ratiosbase line, day 0Calcul of posterior/anterior ratios for both the PVWMH and CC-PVWMH
Anterior PVWMHBase line, Day 0Comparison of anterior PVWMH between CAA group and HA group.
Posterior PVWMHBase line, Day 0Comparison of posterior PVWMH between CAA group and HA group.
Total PVWMHBase line, Day 0Comparison of total PVWMH between CAA group and HA group.
Posterior/anterior PVWMH ratioBase line, Day 0Comparison of the posterior/anterior PVWMH ratio between CAA and HA groups.
anterior CC-PVWMHBase line, Day 0Comparison of anterior CC-PVWMH between CAA group and HA group.
Posterior CC-PVWMHBase line, Day 0Comparison of posterior CC-PVWMH between CAA group and HA group.
Total PVWMH and posterior/anterior CC-PVWMH ratioBase line, Day 0Comparison of total PVWMH and posterior/anterior CC-PVWMH ratio between CAA group and HA group.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026